Incannex Healthcare operates as a speculative, pre-commercial R&D entity with negligible revenue, necessitating constant capital injections to sustain its clinical pipeline. The firm's reliance on share-based compensation, which reached $3.2 million in 2026Q2,...
Price trend, volume and key moving averages
Trailing total returns as of 10/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 25, 2026 | -$0.14-207.7% vs $0.13 | — vs $200,000 |
Q2 2026 May 15, 2026 | -$0.35+41.7% vs -$0.60 | — vs $200,000 |
Q1 2026 Feb 13, 2026 | -$0.60+0.0% vs -$0.60 | — vs $200,000 |
Q4 2025 Nov 14, 2025 | -$0.60+94.9% vs -$11.70 | — vs $200,000 |
Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations.
Scilex (NASDAQ: SCLX - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Analyst Recommendations This is a breakdown of recent
Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026 NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today provides a corporate update reporting the dosing of the first patient in its DReAMzz Phase 2 study of IHL-42X in obstructive sleep apnea, the grant of a U.S. composition patent covering IHL-42X, and a cash position of approximately $70 million with no debt.
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation
Benchmark IXHL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Incannex Healthcare Limited (IXHL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.82 | $34.73M | -0.07 | 616.67% | -54517.44% | -381.09% | — | |
| $10.75 | $1.45B | -3.49 | — | — | -398.21% | — | |
| $42.79 | $3.23B | -20.77 | — | — | -102.48% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $6.09 | $1.13B | -14.13 | — | — | -81% | — | |
| $22.09 | $337.58M | 24.82 | 13.74% | 4.48% | 12.66% | — |
Incannex Healthcare Limited (IXHL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Incannex Healthcare Limited (IXHL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 9, 2026·SEC
Jun 10, 2026·SEC
Jun 9, 2026·SEC
Get notified when IXHL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Incannex Healthcare Limited (IXHL) stock FAQ — growth, dividends, profitability & financials explained
Incannex Healthcare Limited (IXHL) reported $0.1M in revenue for fiscal year 2025.
Incannex Healthcare Limited (IXHL) grew revenue by 616.7% over the past year. This is strong growth.
Incannex Healthcare Limited (IXHL) reported a net loss of $58.8M for fiscal year 2025.
Incannex Healthcare Limited (IXHL) has a return on equity (ROE) of -381.1%. Negative ROE indicates the company is unprofitable.
Incannex Healthcare Limited (IXHL) had negative free cash flow of $12.5M in fiscal year 2025, likely due to heavy capital investments.
